Background: L-carnitine can be metabolized to trimethylamine N-oxide (TMAO), a molecule that promotes atherogenesis through its interaction with macrophages and lipid metabolism. Objective: The aim of the present study was to assess whether L-carnitine supplementation may promote changes in selected serum biomarkers of atherosclerosis. Methods: Before the start, in the mid-point and after completing the 24-weeks supplementation protocol, fasting blood samples were taken from the antecubital vein. Plasma free L-carnitine and TMAO were determined by the UPLC/MS/MS method. Serum proteins were determined by the enzyme immunoassay method using commercially available kits. Total cholesterol, high-density lipoprotein-cholesterol, low-density lipoprotein-cholesterol, and triglycerides have been determined using standard automatic analyzer. Results: L-carnitine supplementation elevated fasting plasma carnitine in the mid-point of our study and it remained increased until the end of supplementation period. Moreover, it induced tenfold increase in plasma TMAO concentration but did not affect serum C-reactive protein, interleukin-6, tumour necrosis factor-α, L-selectin, P-selectin, vascular cell adhesion molecule-1, intercellular adhesion molecule-1 or lipid profile markers. Conclusion: We demonstrated that -although oral L-carnitine supplementation significantly -increased plasma TMAO concentration, no lipid profile changes or other markers of adverse cardiovascular events were detected in healthy aged women over the period of 24 weeks.

Keywords:
Aging, Cardiovascular health, Inflammation
1.
Rudolf J, Lewandrowski KB: Cholesterol, lipoproteins, high-sensitivity c-reactive protein, and other risk factors for atherosclerosis. Clin Lab Med 2014; 34: 113–127.
2.
Wu MY, Li CJ, Hou MF, Chu PY: New insights into the role of inflammation in the pathogenesis of atherosclerosis. Int J Mol Sci 2017; 18:E2034.
3.
Yurdagul A Jr, Finney AC, Woolard MD, Orr AW: The arterial microenvironment: the where and why of atherosclerosis. Biochem J 2016; 473: 1281–1295.
4.
Pradhan AD, Shrivastava S, Cook NR, Rifai N, Creager MA, Ridker PM: Symptomatic peripheral arterial disease in women: nontraditional biomarkers of elevated risk. Circulation 2008; 117: 823–831.
5.
Ridker PM, Stampfer MJ, Rifai N: Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA 2001; 285: 2481–2485.
6.
Pamukcu B, Lip GY, Devitt A, Griffiths H, Shantsila E: The role of monocytes in atherosclerotic coronary artery disease. Ann Med 2010; 42: 394–403.
7.
Patzelt J, Langer HF: Platelets in angiogenesis. Curr Vasc Pharmacol 2012; 10: 570–577.
8.
Blann AD, Nadar SK, Lip GY: The adhesion molecule P-selectin and cardiovascular disease. Eur Heart J 2003; 24: 2166–2179.
9.
Hwang SJ, Ballantyne CM, Sharrett AR, Smith LC, Davis CE, Gotto AM Jr, Boerwinkle E: Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the atherosclerosis risk in communities (ARIC) study. Circulation 1997; 96: 4219–4225.
10.
Koeth RA, Wang Z, Levison BS, Buffa JA, Org E, Sheehy BT, Britt EB, Fu X, Wu Y, Li L, Smith JD, DiDonato JA, Chen J, Li H, Wu GD, Lewis JD, Warrier M, Brown JM, Krauss RM, Tang WH, Bushman FD, Lusis AJ, Hazen SL: Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat Med 2013; 19: 576–585.
11.
Wang Z, Klipfell E, Bennett BJ, Koeth R, Levison BS, Dugar B, Feldstein AE, Britt EB, Fu X, Chung YM, Wu Y, Schauer P, Smith JD, Allayee H, Tang WH, DiDonato JA, Lusis AJ, Hazen SL: Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 2011; 472: 57–63.
12.
Tang WH, Wang Z, Levison BS, Koeth RA, Britt EB, Fu X, Wu Y, Hazen SL: Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. N Engl J Med 2013; 368: 1575–1584.
13.
Rossner R, Kaeberlein M, Leiser SF: Flavin-containing monooxygenases in aging and disease: Emerging roles for ancient enzymes. J Biol Chem 2017; 292: 11138–11146.
14.
Gruppen EG, Garcia E, Connelly MA, Jeyarajah EJ, Otvos JD, Bakker SJL, Dullaart RPF: TMAO is associated with mortality: impact of modestly impaired renal function. Sci Rep 2017; 7: 13781.
15.
Suzuki T, Heaney LM, Bhandari SS, Jones DJ, Ng LL: Trimethylamine N-oxide and prognosis in acute heart failure. Heart 2016; 102: 841–848.
16.
Tang WH, Wang Z, Kennedy DJ, Wu Y, Buffa JA, Agatisa-Boyle B, Li XS, Levison BS, Hazen SL: Gut microbiota-dependent trimethylamine N-oxide (TMAO) pathway contributes to both development of renal insufficiency and mortality risk in chronic kidney disease. Circ Res 2015; 116: 448–455.
17.
Chen ML, Zhu XH, Ran L, Lang HD, Yi L, Mi MT: Trimethylamine-N-oxide induces vascular inflammation by activating the NLRP3 inflammasome through the SIRT3-SOD2-mtROS signaling pathway. J Am Heart Assoc 2017; 6:e006347.
18.
Ma G, Pan B, Chen Y, Guo C, Zhao M, Zheng L, Chen B: Trimethylamine N-oxide in atherogenesis: impairing endothelial self-repair capacity and enhancing monocyte adhesion. Biosci Rep 2017; 37:BSR20160244.
19.
Fukami K, Yamagishi S, Sakai K, Kaida Y, Yokoro M, Ueda S, Wada Y, Takeuchi M, Shimizu M, Yamazaki H, Okuda S: Oral L-carnitine supplementation increases trimethylamine-N-oxide but reduces markers of vascular injury in hemodialysis patients. J Cardiovasc Pharmacol 2015; 65: 289–295.
20.
Miller MJ, Bostwick BL, Kennedy AD, Donti TR, Sun Q, Sutton VR, Elsea SH: Chronic oral L-carnitine supplementation drives marked plasma TMAO elevations in patients with organic acidemias despite dietary meat restrictions. JIMD Rep 2016; 30: 39–44.
21.
Sawicka AK, Hartmane D, Lipinska P, Wojtowicz E, Lysiak-Szydlowska W, Olek RA: L-carnitine supplementation in older women. a pilot study on aging skeletal muscle mass and function. Nutrients 2018; 10:E255.
22.
Grinberga S, Dambrova M, Latkovskis G, Strele I, Konrade I, Hartmane D, Sevostjanovs E, Liepinsh E, Pugovics O: Determination of trimethylamine-N-oxide in combination with L-carnitine and γ-butyrobetaine in human plasma by UPLC/MS/MS. Biomed Chromatogr 2015; 29: 1670–1674.
23.
Obeid R, Awwad HM, Rabagny Y, Graeber S, Herrmann W, Geisel J: Plasma trimethylamine N-oxide concentration is associated with choline, phospholipids, and methyl metabolism. Am J Clin Nutr 2016; 103: 703–711.
24.
Rohrmann S, Linseisen J, Allenspach M, von Eckardstein A, Muller D: Plasma concentrations of Trimethylamine-N-oxide are directly associated with dairy food consumption and low-grade inflammation in a German adult population. J Nutr 2016; 146: 283–289.
25.
Zhang AQ, Mitchell SC, Smith RL: Dietary precursors of trimethylamine in man: a pilot study. Food Chem Toxicol 1999; 37: 515–520.
26.
Zhao Y, Yang N, Gao J, Li H, Cai W, Zhang X, Ma Y, Niu X, Yang G, Zhou X, Li Y: The effect of different L-carnitine administration routes on the development of atherosclerosis in apoe knockout mice. Mol Nutr Food Res 2018; 62.
27.
Yazdekhasti N, Brandsch C, Schmidt N, Schloesser A, Huebbe P, Rimbach G, Stangl GI: Fish protein increases circulating levels of trimethylamine-N-oxide and accelerates aortic lesion formation in apoE null mice. Mol Nutr Food Res 2016; 60: 358–368.
28.
Lo Sasso G, Schlage WK, Boue S, Veljkovic E, Peitsch MC, Hoeng J: The Apoe(-/-) mouse model: a suitable model to study cardiovascular and respiratory diseases in the context of cigarette smoke exposure and harm reduction. J Transl Med 2016; 14: 146.
29.
Collins HL, Drazul-Schrader D, Sulpizio AC, Koster PD, Williamson Y, Adelman SJ, Owen K, Sanli T, Bellamine A: L-carnitine intake and high trimethylamine N-oxide plasma levels correlate with low aortic lesions in ApoE(-/-) transgenic mice expressing CETP. Atherosclerosis 2016; 244: 29–37.
30.
Sun X, Jiao X, Ma Y, Liu Y, Zhang L, He Y, Chen Y: Trimethylamine N-oxide induces inflammation and endothelial dysfunction in human umbilical vein endothelial cells via activating ROS-TXNIP-NLRP3 inflammasome. Biochem Biophys Res Commun 2016; 481: 63–70.
31.
Ke Y, Li D, Zhao M, Liu C, Liu J, Zeng A, Shi X, Cheng S, Pan B, Zheng L, Hong H: Gut flora-dependent metabolite Trimethylamine-N-oxide accelerates endothelial cell senescence and vascular aging through oxidative stress. Free Radic Biol Med 2018; 116: 88–100.
32.
Empl MT, Kammeyer P, Ulrich R, Joseph JF, Parr MK, Willenberg I, Schebb NH, Baumgartner W, Rohrdanz E, Steffen C, Steinberg P: The influence of chronic L-carnitine supplementation on the formation of preneoplastic and atherosclerotic lesions in the colon and aorta of male F344 rats. Arch Toxicol 2015; 89: 2079–2087.
33.
Kaysen GA, Johansen KL, Chertow GM, Dalrymple LS, Kornak J, Grimes B, Dwyer T, Chassy AW, Fiehn O: Associations of trimethylamine N-oxide with nutritional and inflammatory biomarkers and cardiovascular outcomes in patients new to dialysis. J Ren Nutr 2015; 25: 351–356.
34.
Mueller DM, Allenspach M, Othman A, Saely CH, Muendlein A, Vonbank A, Drexel H, von Eckardstein A: Plasma levels of trimethylamine-N-oxide are confounded by impaired kidney function and poor metabolic control. Atherosclerosis 2015; 243: 638–644.
35.
Veeravalli S, Karu K, Scott F, Fennema D, Phillips IR, Shephard EA: Effect of flavin-containing monooxygenase genotype, mouse strain, and gender on trimethylamine N-oxide production, plasma cholesterol concentration, and an index of atherosclerosis. Drug Metab Dispos 2018; 46: 20–25.
36.
Weinert CH, Empl MT, Kruger R, Frommherz L, Egert B, Steinberg P, Kulling SE: The influence of a chronic L-carnitine administration on the plasma metabolome of male Fischer 344 rats. Mol Nutr Food Res 2017; 61.
37.
Tousoulis D, Kampoli AM, Papageorgiou N, Androulakis E, Antoniades C, Toutouzas K, Stefanadis C: Pathophysiology of atherosclerosis: the role of inflammation. Curr Pharm Des 2011; 17: 4089–4110.
38.
De Caterina R, Massaro M, Scoditti E, Annunziata Carluccio M: Pharmacological modulation of vascular inflammation in atherothrombosis. Ann N Y Acad Sci 2010; 1207: 23–31.
39.
Tzoulaki I, Murray GD, Lee AJ, Rumley A, Lowe GD, Fowkes FG: C-reactive protein, interleukin-6, and soluble adhesion molecules as predictors of progressive peripheral atherosclerosis in the general population: edinburgh artery study. Circulation 2005; 112: 976–983.
40.
Packard RR, Libby P: Inflammation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction. Clin Chem 2008; 54: 24–38.
41.
Signorelli SS, Anzaldi M, Libra M, Navolanic PM, Malaponte G, Mangano K, Quattrocchi C, Di Marco R, Fiore V, Neri S: Plasma levels of inflammatory biomarkers in peripheral arterial disease: results of a cohort study. Angiology 2016; 67: 870–874.
42.
Della Corte V, Tuttolomondo A, Pecoraro R, Di Raimondo D, Vassallo V, Pinto A: Inflammation, endothelial dysfunction and arterial Stiffness as therapeutic targets in cardiovascular medicine. Curr Pharm Des 2016; 22: 4658–4668.
43.
Koenig W, Lowel H, Baumert J, Meisinger C: C-reactive protein modulates risk prediction based on the Framingham Score: implications for future risk assessment: results from a large cohort study in southern Germany. Circulation 2004; 109: 1349–1353.
44.
Rafraf M, Karimi M, Jafari A: Effect of L-carnitine supplementation in comparison with moderate aerobic training on serum inflammatory parameters in healthy obese women. J Sports Med Phys Fitness 2015; 55: 1363–1370.
45.
Sahebkar A: Effect of L-carnitine supplementation on circulating C-reactive protein levels: a systematic review and meta-analysis. J Med Biochem 2015; 34: 151–159.
46.
Malaguarnera M, Gargante MP, Russo C, Antic T, Vacante M, Malaguarnera M, Avitabile T, Li Volti G, Galvano F: L-carnitine supplementation to diet: a new tool in treatment of nonalcoholic steatohepatitis – a randomized and controlled clinical trial. Am J Gastroenterol 2010; 105: 1338–1345.
47.
van Diepen JA, Berbee JF, Havekes LM, Rensen PC: Interactions between inflammation and lipid metabolism: relevance for efficacy of anti-inflammatory drugs in the treatment of atherosclerosis. Atherosclerosis 2013; 228: 306–315.
48.
Badimon L, Vilahur G: LDL-cholesterol versus HDL-cholesterol in the atherosclerotic plaque: inflammatory resolution versus thrombotic chaos. Ann N Y Acad Sci 2012; 1254: 18–32.
49.
Huang H, Song L, Zhang H, Zhang H, Zhang J, Zhao W: Influence of L-carnitine supplementation on serum lipid profile in hemodialysis patients: a systematic review and meta-analysis. Kidney Blood Press Res 2013; 38: 31–41.
50.
Mohammadi H, Djalali M, Daneshpazhooh M, Honarvar NM, Chams-Davatchi C, Sepandar F, Fakhri Z, Yaghubi E, Zarei M, Javanbakht MH: Effects of L-carnitine supplementation on biomarkers of oxidative stress, antioxidant capacity and lipid profile, in patients with pemphigus vulgaris: a randomized, double-blind, placebo-controlled trial. Eur J Clin Nutr 2018; 72: 99–104.
51.
Malek Mahdavi A, Mahdavi R, Kolahi S, Zemestani M, Vatankhah AM: L-carnitine supplementation improved clinical status without changing oxidative stress and lipid profile in women with knee osteoarthritis. Nutr Res 2015; 35: 707–715.
52.
Woodhouse PR, Khaw KT, Plummer M: Seasonal variation of serum lipids in an elderly population. Age Ageing 1993; 22: 273–278.
53.
Ussher JR, Lopaschuk GD, Arduini A: Gut microbiota metabolism of L-carnitine and cardiovascular risk. Atherosclerosis 2013; 231: 456–461.
54.
Johri AM, Heyland DK, Hetu MF, Crawford B, Spence JD: Carnitine therapy for the treatment of metabolic syndrome and cardiovascular disease: evidence and controversies. Nutr Metab Cardiovasc Dis 2014; 24: 808–814.
55.
Cho CE, Caudill MA: Trimethylamine-N-Oxide: Friend, Foe, or Simply Caught in the Cross-Fire? Trends Endocrinol Metab 2017; 28: 121–130.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.